ADERONKE AJALA, MD
Hematology & Oncology Physician · STATE COLLEGE, PA
Individual Active NPI 1689015042
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 499 | 219,869 | $11,148,309 | $4,327,276 | $3,442,504 |
| 2023 | 427 | 142,751 | $7,871,136 | $2,562,348 | $2,033,234 |
| 2022 | 402 | 145,933 | $9,902,424 | $3,257,509 | $2,596,905 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 27,030 | $0 | $0 |
| J9271 | Injection, pembrolizumab, 1 mg | 19,800 | $56 | $45 |
| J1756 | Injection, iron sucrose, 1 mg | 12,000 | $0 | $0 |
| J1453 | Injection, fosaprepitant, 1 mg | 10,650 | $0 | $0 |
| J9267 | Injection, paclitaxel, 1 mg | 6,096 | $0 | $0 |
| J0897 | Injection, denosumab, 1 mg | 6,060 | $26 | $21 |
| J0185 | Injection, aprepitant, 1 mg | 3,510 | $2 | $1 |
| J9030 | Bcg live intravesical instillation, 1 mg | 1,900 | $3 | $2 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1,590 | $31 | $25 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,434 | $0 | $0 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 1,160 | $1 | $1 |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 468 | $62 | $49 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Hematology & Oncology Physician | 207RH0003X | ✓ | MD468171 | PA |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Hematology & Oncology Physician providers in Pennsylvania
- NPI 1578903795
- NPI 1477891711
- NPI 1528019056
- NPI 1659340818
- NPI 1023215670
- NPI 1063875227
- NPI 1629874748
- NPI 1730144304
See all Hematology & Oncology Physician providers in Pennsylvania →
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.